Larimar Therapeutics, Inc.LRMRNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank86
5Y CAGR+17.0%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
+17.0%/yr
Long-term compound
Percentile
P86
Within normal range
vs 5Y Ago
2.2x
Strong expansion
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 110.46% |
| 2024 | 164.83% |
| 2023 | 14.10% |
| 2022 | -36.84% |
| 2021 | 22.86% |
| 2020 | 50.32% |
| 2019 | -58.02% |
| 2018 | 18.66% |
| 2017 | 4.94% |
| 2016 | -27.18% |